SurModics (SRDX) Tops Q2 EPS by 15c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update
April 29, 2020 4:05 PM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.
Summary of Second Quarter and Recent Highlights
Revenue of $22.8 million, an increase of 1% year-over-year GAAP EPS of $0.11, non-GAAP EPS of $0.04 Cash and short-term investments of $48.4 million CE Mark clearance received for Telemark coronary/peripheral support microcatheter Partnership announced with Cook Medical for... More